The effect of interatechal magnesium sulfate on the quality of block in elective cesarean section

Comparing the effect of different dose of interatechal magnesium sulfate on quality of sensory-motor block in elective cesarean section

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201107112405N8

Enrollment

132

Registered

2011-11-05

Start date

2010-08-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Complications of anesthesia during pregnancy. Other complications of anesthesia during pregnancy

Interventions

Intervention 1: 2.5 cc Bupivacaine 0.5%+ 0.2cc Normal Saline. Duration of intervention: single dose in 10 seconds spinal injection. Duration of treatment: During spinal anesthesia in operating room. I

Treatment - Drugs

2.5 cc Bupivacaine 0.5%+ 0.2cc Normal Saline. Duration of intervention: single dose in 10 seconds spinal injection. Duration of treatment: During spinal anesthesia in operating room

2.5 cc Bupivacaine 0.5%+ 0.1 cc Normal Saline+ 0.1 cc Magnesium sulfate 50%. Duration of intervention: single dose in 10 seconds spinal injection. Duration of treatment: During spinal anesthesia in op

2.5 cc Bupivacaine 0.5%+ 0.05 cc Normal Saline+ 0.15 cc Magnesium sulfate 50%. Duration of intervention: single dose in 10 seconds spinal injection. Duration of treatment: During spinal anesthesia in

2.5 cc Bupivacaine 0.5%+ 0.2 cc Magnesium sulfate 50. Duration of intervention: single dose in 10 seconds spinal injection. Duration of treatment: During spinal anesthesia in operating room

Eligibility

Sex/Gender

Female

Age

15 Years to 50 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria: Parturients; ASA physical status I-II; scheduled for elective cesarean section; under spinal anesthesia; Exclusion Criteria: suspicious to bleeding disturbances; atopia; diabetes mellitus; existence of liver or kidney diseases; drugs abuse; hypertension of pregnancy; preeclampsia

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Sensory block onset time. Timepoint: time from intratechal injection to T6 dermatomal level. Method of measurement: pin prick test with needle.;Motor block onset time. Timepoint: time from intratechal injection to ankle flexion. Method of measurement: ask to parturient for flexion of ankle- measure with watch in minute.;Duration of motor block. Timepoint: time from intrathecal injection to ability of ankle flexion. Method of measurement: with watch in minute.;Duration of sensory block. Timepoint: time from intrathecal injection to presence of pain. Method of measurement: with watch in minute.	—

Measure

Time frame

Sensory block onset time. Timepoint: time from intratechal injection to T6 dermatomal level. Method of measurement: pin prick test with needle.;Motor block onset time. Timepoint: time from intratechal injection to ankle flexion. Method of measurement: ask to parturient for flexion of ankle- measure with watch in minute.;Duration of motor block. Timepoint: time from intrathecal injection to ability of ankle flexion. Method of measurement: with watch in minute.;Duration of sensory block. Timepoint: time from intrathecal injection to presence of pain. Method of measurement: with watch in minute.

—

Secondary

Measure	Time frame
Pain intensity. Timepoint: recovery room(0) ,0.5 , 1, 1.5, 2, 2.5, 3, 3.5 and 4 hours postoperative. Method of measurement: Visual Analogous Scale (VAS) and scoring from 0 to 10.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Mitra Jabalameli

Isfahan University of Medical Sciences

jabalameli@med.mui.ac.ir+98 31162555551532

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026